Medications for Spasticity Management
The first-line oral medications for spasticity management are tizanidine, baclofen, and dantrolene, with botulinum toxin injections recommended for focal spasticity, and intrathecal baclofen reserved for severe cases unresponsive to other treatments. 1, 2
Stepwise Approach to Spasticity Management
Spasticity, defined as velocity-dependent hyperactivity of tonic stretch reflexes, affects approximately 25-43% of stroke patients within the first year and can significantly impact mortality, morbidity, and quality of life through pain, contractures, and functional limitations 1, 2.
First-Line Non-Pharmacological Interventions
- Antispastic positioning
- Range of motion exercises
- Stretching
- Splinting
- Serial casting
Oral Medications
Tizanidine
Oral Baclofen
Dantrolene
- Acts directly on muscle
- Limited trial data supporting use in stroke 1
- Benefit of fewer cognitive side effects
CAUTION: Diazepam and other benzodiazepines are contraindicated during stroke recovery due to possible deleterious effects on recovery and sedation side effects 1
Injectable Treatments for Focal Spasticity
Botulinum Toxin
Phenol/Alcohol Nerve Blocks
- Alternative for selected patients with disabling or painful spasticity 1
Advanced Interventions for Severe Spasticity
Intrathecal Baclofen
- Reserved for severe spastic hypertonia unresponsive to other treatments 2, 7
- Can be considered as early as 3-6 months after stroke for refractory cases 7
- Delivers baclofen directly to CSF at concentrations less than 1/100th of oral doses 6
- Requires surgical implantation of pump and reservoir
- Risk of withdrawal syndrome if delivery is interrupted 7
Neurosurgical Procedures
- Selective dorsal rhizotomy or dorsal root entry zone lesions
- Significant risks involved
- Limited clinical trial evidence 1
Special Considerations
- Monitoring: Regular assessment of efficacy, side effects, and functional outcomes is essential
- Side Effect Management: Sedation is common with oral medications (10-75% incidence) 5, 8
- Withdrawal Risk: Abrupt cessation of baclofen (especially intrathecal) can lead to severe withdrawal syndrome 7
- Functional Impact: Treatment should focus on improving pain, skin hygiene, and function rather than just reducing muscle tone 1, 2
Algorithm for Medication Selection
For generalized spasticity:
- Start with tizanidine if short-duration relief is needed for specific activities
- Consider baclofen for more continuous relief, starting at low doses and titrating up
- Use dantrolene when cognitive side effects must be minimized
For focal spasticity:
- Botulinum toxin injections are first-line therapy
- Consider phenol/alcohol blocks as alternatives
For severe, refractory spasticity:
- Consider intrathecal baclofen when oral medications fail or cause intolerable side effects
- Reserve neurosurgical procedures for the most resistant cases
By following this evidence-based approach to medication selection for spasticity management, clinicians can optimize outcomes while minimizing adverse effects that could negatively impact mortality, morbidity, and quality of life.